Evaluation and Management of Hypoactive Sexual Desire Disorder
Introduction: Hypoactive sexual desire disorder (HSDD) often has a negative impact on the health and quality of life of women; however, many women do not mention—let alone discuss—this issue with their physicians. Providers of gynecologic services have the opportunity to address this subject with th...
Main Authors: | Anita H. Clayton, MD, Sheryl A. Kingsberg, PhD, Irwin Goldstein, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Oxford University Press
2018-06-01
|
Series: | Sexual Medicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2050116118300266 |
Similar Items
-
Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire Disorder
by: James A. Simon, MD, et al.
Published: (2022-12-01) -
Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin
by: James A. Simon, MD, et al.
Published: (2022-02-01) -
What Sexual Behaviors Relate to Decreased Sexual Desire in Women? A Review and Proposal for End Points in Treatment Trials for Hypoactive Sexual Desire Disorder
by: Robert Pyke, MD, PhD, et al.
Published: (2017-06-01) -
Bremelanotide for Hypoactive Sexual Desire Disorder
by: T. S. Sathyanarayana Rao, et al.
Published: (2020-01-01) -
Drug flibanserin–in hypoactive sexual desire disorder
by: Pugazhenthan Thangaraju, et al.
Published: (2022-06-01)